The board of directors of Alphamab Oncology (Company) announced that Mr. QIU Yu Min ('Mr. Qiu') has tendered his resignation from the position as a non-executive Director with effect from June 16, 2022 due to his other work commitments. Following Mr. Qiu's resignation as a non-executive Director, he ceased to be a member of the audit committee of the Company. The Board announced that, Dr. GUO Zijian, an independent non-executive Director, has been appointed as a member of the Audit Committee with effect from June 16, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.81 HKD | +3.00% | -9.25% | -27.56% |
02/05 | Alphamab Oncology's 2023 Loss Narrows as Revenue Rises | MT |
10/04 | Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.56% | 58Cr | |
+67.53% | 6.39TCr | |
-0.77% | 4.18TCr | |
+44.98% | 4.07TCr | |
-10.87% | 2.71TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.87TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.21TCr | |
+27.41% | 1.21TCr |
- Stock Market
- Equities
- 9966 Stock
- News Alphamab Oncology
- Alphamab Oncology Announces Board and Committee Changes